Aggressive purchases in Personalis: what's behind the move?
We identified unusual activity in Personalis (PSNL).
Tempus AI, a strategic partner and major stakeholder, aggressively increased its holdings in the company in the last quarter.
The move is generating significant interest among investors in the biotech and genomics sectors.
So first of all, who is Personalis? Personalis operates at the forefront of science, developing personalized medicine solutions for cancer patients.
Its main product focuses on MRD (Minimal Residual Disease) technology – blood and tissue tests capable of detecting minimal cancer remnants in the body after treatment.
The big advantage here is accuracy; the test can detect the disease long before standard scans, like CT, would notice it.
The company is currently at a critical juncture, awaiting Medicare (the US government health insurance) approval for its next-generation tests.
Such approval could boost the company's revenue and make the technology a widespread treatment standard.
The buyer who knows the company 'from the inside'? The acquirer, Tempus AI, is a global leader in using artificial intelligence for clinical data analysis.
Its founder and CEO, Eric Lefkofsky (co-founder of Groupon), is considered a very influential figure in the medical technology world.
The importance of the acquisition stems from Tempus's status within Personalis:
It is defined as a stakeholder (holding over 10%).
It has representation on the board of directors (Director).
It is a strategic partner for commercializing MRD tests.
In simple terms – as a strategic partner and stakeholder – Tempus has access to information not yet public, including preliminary trial results and progress with regulatory authorities (FDA).
Let's proceed to the transaction analysis – a series of insider purchases.
During November and December 2025, we identified that Tempus made a series of daily and intensive purchases:
The purchases were made almost daily, even as the stock price rose from $7.6 to $11.00.
The fact that an institutional entity continues to buy at rising prices raises questions...
As of the end of the purchase series, Tempus holds over 13 million shares of Personalis.
The strategic significance of the move
The move raises many questions, and there are several possible reasons for such a move:
1. The suspicion – synergy and potential acquisition? Tempus is the most natural buyer for Personalis; could a massive purchase of shares in the open market be the first step towards a takeover or merger between the companies?
2. The big question looming – timing. Does the concentration of purchases at the end of 2025 hint at an expectation of significant milestones during 2026?
The main event to focus on now is the announcement of reimbursement for MRD tests.
This is the company's barrier to commercial breakthrough.
Is Tempus betting that the outcome will be positive?
We are monitoring.